Business
MediBeacon® Next Generation TGFR™ System Receives FDA Approval
MediBeacon® TGFRTM System is a first-in-kind product for point of care kidney function assessmentCenters of Excellence commercialization in select academic medical centers begins in early 2026 NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7
About this update from Innovate Corp.
[{"type":"image","alt":"INNOVATE Corp.","displaySize":"","headline":null,"caption":"INNOVATE Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":155,"url":"https://media.zenfs.com/en/globenewswire.com/f6839c69bcfd01d6eebbc83e70475620"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/HRT7VOVi6Bwl5KlGPoGQeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxNztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f6839c69bcfd01d6eebbc83e70475620","width":300,"height":155}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"MediBeacon® TGFRTM System is a first-in-kind product for point of care kidney function assessment","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Centers of Excellence commercialization in select academic medical centers begins in early 2026","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":192,"olType":false},{"type":"text","content":"NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection, in which INNOVATE owns a 44.7% equity interest, has received approval from the U.S. Food and Drug Administration (FDA) for the next generation MediBeacon® TGFRTM System including the latest TGFRTM Reusable Sensor.","length":491,"tagName":"p"},{"type":"text","content":"The TGFR System enables kidney function assessment at the point of care by measuring the clearance rate of Lumitrace® (relmapirazin), a non-radioactive, non-iodinated fluorescent GFR agent. The TGFR Reusable Sensor placed on the skin measures the change in Lumitrace fluorescence intensity as a function of time.","length":312,"tagName":"p"},{"type":"text","content":"The latest TGFR Reusable Sensor has been designed for patient comfort, ease of application, and reusability. It also lowers the cost compared to the single use TGFR Sensor previously approved by the FDA.","length":213,"tagName":"p"},{"type":"text","content":"The TGFR System was the subject of the lead peer-reviewed article featured on the cover of the Journal of the American Society of Nephrology (JASN) in August 2025.1 The article reviewed the first use of the transdermal GFR (tGFR) methodology in patie...